Novo Nordisk lifts 2026 outlook on Wegovy pill demand, but pricing and competition weigh

What happened

In its Q2 earnings call, Novo Nordisk raised full-year guidance after oral Wegovy demand surged, bringing in millions of new patients and driving volume growth. However, management continued to warn that U.S. realized prices are declining, partially offsetting volume gains, and that Lilly’s oral Foundayo is intensifying competition. The DeepValue master report had already flagged these headwinds, assigning a WAIT rating until economic stabilization materializes. The call did not dispel the overhang of pricing pressure or patent losses, and the second half will test whether Medicare expansion and sustained oral uptake can offset these forces. Demand is strong, but the path to durable revenue per script remains uncertain.

Implication

While oral Wegovy’s early traction and the guidance lift are incrementally positive, they do not guarantee that Novo can escape the pricing vise or Lilly’s encroachment. The master report’s base case still relies on volume growth offsetting price declines, but Q2 provided no clear evidence that net revenue per script has bottomed. Investors should watch for H2 sell-through data and the September Capital Markets Day for concrete plans to protect economics. Until then, the stock remains a wait-and-see story, with risk skewed toward further multiple compression if pricing pressure persists. A more constructive entry point would require U.S. adjusted sales growth to turn positive and oral Wegovy scripts to stay above 200,000 weekly.

Thesis delta

The Q2 update slightly edges conviction toward the base case, as oral Wegovy demand exceeds initial expectations, but U.S. pricing remains the critical unresolved variable. The thesis holds: economic recovery is not yet proven, and the next catalysts (H2 sell-through, CMD) are still needed to justify a more constructive stance.